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PMajor Role for Hypoxia Inducible Factor-1
and the Endothelin System in Promoting
Myocardial Infarction and Hypertension
in an Animal Model of Obstructive Sleep Apnea
Elise Belaidi, PHD,* Marie Joyeux-Faure, PHD,*† Christophe Ribuot, PHD,*†
Sandrine H. Launois, MD, PHD,*†‡ Patrick Levy, MD, PHD,*†‡ Diane Godin-Ribuot, PHD*†
Grenoble, France
Objectives Our aim was to investigate the involvement of the endothelin (ET) system in the cardiovascular consequences of
intermittent hypoxia (IH).
Background Obstructive sleep apnea (OSA) syndrome is an important risk factor for cardiovascular morbidity. Chronic IH, a
major component of OSA, is thought to be responsible for most of the cardiovascular complications occurring
during OSA, but the underlying mechanisms remain to be determined.
Methods Chronic IH was applied in rats genetically prone to develop hypertension (spontaneous hypertensive rats [SHR])
and their normotensive controls. The cardiovascular effects were assessed in vivo and in Langendorff perfused
hearts. Hypoxia inducible factor (HIF)-1 activity and targeting of the myocardial ET-1 gene and activation of the
ET system were investigated using tissue chromatin immunoprecipitation, enzyme-linked immunoadsorbent as-
say, immunostaining, and Western blotting.
Results Chronic IH enhanced hypertension development and infarct size in SHR compared with that seen in control rats.
This was accompanied by an increase in myocardial big ET-1, ET-1, and ET-A receptor expression and by an en-
hanced coronary vascular reactivity to ET-1 in SHR only. Myocardial HIF-1 activity was increased, and HIF-1 was
shown to be linked to the promoter of the myocardial ET-1 gene after chronic IH only. Moreover, administration
of bosentan, a mixed ET receptor antagonist, during chronic IH prevented both the increase in blood pressure
and in infarct size.
Conclusions In SHR, activation of the ET system, mediated by HIF-1 activity, is responsible for the enhanced susceptibility to
chronic IH and for its associated cardiovascular consequences leading to hypertension and ischemic injury. Fur-
thermore, the beneficial effects of bosentan suggest exploring ET antagonists as possible therapeutic tools in
OSA. (J Am Coll Cardiol 2009;53:1309–17) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.050p
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sbstructive sleep apnea (OSA) syndrome is characterized
y recurrent episodes of pharyngeal collapse occurring
uring sleep, leading to intermittent hypoxia (IH) and
ypercapnia and terminated by an arousal. OSA is a
rowing health concern as it affects up to 5% of middle-aged
en and women with a higher prevalence in the elderly (1).
oreover, OSA is recognized as an important and inde-
rom *INSERM, Grenoble, France; †Université Joseph Fourier, Faculté de
édecine-Pharmacie, Grenoble, France; and ‡CHU de Grenoble, Hôpital A.
ichallon, Laboratoire EFCR, Grenoble, France. This study was supported, in part,
y a grant from AGIR à dom (Grenoble, France). Dr. Launois is the recipient of an
REA award from Actelion Pharmaceuticals for a clinical project on sleep apnea
atients.p
Manuscript received May 6, 2008; revised manuscript received December 12, 2008,
ccepted December 15, 2008.endent risk factor for systemic hypertension (2), arrhyth-
ias (3), stroke (4), and coronary heart disease (5). Patients
ith OSA have an increased rate of cardiovascular morbid-
ty and mortality (6). Last, OSA is also associated with
ardiovascular subclinical conditions such as diastolic hyper-
ension (7), diastolic ventricular dysfunction (8), and early
therosclerosis (9).
See page 1318
Using various biological markers, numerous studies have
hown an increased oxidative stress in OSA patients with
roduction of reactive oxygen species correlated with the
everity of oxygen desaturations and reversed by continuous
ositive airway pressure (CPAP) treatment (10,11).
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Endothelin in OSA-Related CVD April 14, 2009:1309–17IH appears to be the main
causal factor in the pathogenesis
of cardiovascular complications
in OSA (12). Thus, rodent mod-
els of IH have been extensively
used to study the mechanisms of
OSA-related morbidity. It is
now established that systemic
hypertension (13), dyslipidemia,
and early atherosclerosis (14) as
well as vascular remodeling (15)
occur after only a few weeks of
IH exposure. In addition, chronic
IH enhances myocardial sensitivity
to ischemia, resulting in larger
infarct sizes (16,17). Among the
possible mechanisms responsible
for some of these changes, in-
creased oxidative stress and activa-
tion of the endothelin (ET) system
have been proposed (17–19).
Assessing the ET system in
esponse to IH is well founded. Hypoxia is a powerful
timulus for the production of ET-1 by endothelial cells and
ardiomyocytes; in particular, its expression is increased
nder the hypoxia-inducible factor (HIF)-1 transcriptional
ontrol (20). Although the vasoconstrictor effects of ET-1
ere the first to be characterized, accumulating evidence
hows that it is also a powerful proinflammatory cytokine
21) involved in endothelial dysfunction and atherosclerosis
22). Moreover, ET-1 plasma concentrations are elevated in
SA patients (23–25), positively correlated with the sever-
ty of nocturnal hypoxia (23,25), and corrected by CPAP
reatment (23,24). Rats exposed to chronic IH not only
xhibit increased plasma levels of ET-1 (18) but also
nhanced vascular reactivity to ET-1 (26,27).
The aim of the present study was to characterize the
echanisms and role of the ET system activation in the
evelopment of some of the cardiovascular consequences of
H, namely systemic hypertension and enhanced myocardial
nfarction. To this end, we used a novel approach by
nvestigating animals with an inbred genetic predisposition
o cardiovascular disease, which might render them more
ensitive to IH and thus more prone to develop cardiovas-
ular complications. We chose to perform the study on
pontaneously hypertensive rats (SHR) because they display,
n addition to systemic hypertension, other cardiovascular
isk factors also encountered in OSA such as increased
xidative stress (28). Moreover, the fact that hypertension
evelopment in SHR is not ET-dependent (29) ensures that
T-related alterations can be mainly attributed to IH.
Thus, we hypothesized that SHR exposed to IH would
xhibit a greater response than normotensive control rats,
nd that this enhanced susceptibility could be related to a
Abbreviations
and Acronyms
CPAP  continuous
positive airway pressure
ET  endothelin
HIF  hypoxia-inducible
factor
HRE  hypoxia response
element
IH  intermittent hypoxia
MABP  mean arterial
blood pressure
N  normoxia
OSA  obstructive sleep
apnea syndrome
PCR  polymerase chain
reaction
SHR  spontaneous
hypertensive rats
WKY  Wistar Kyoto ratspecific activation of the ET system. In order to investigate che contribution of HIF-1, we used myocardial chromatin
mmunoprecipitation, a powerful technique that allows the
irect evaluation of transcription factor binding on gene
romoters in vivo. Finally, to confirm the role of the ET
ystem in the development of the cardiovascular complica-
ions, we evaluated the effects of oral administration of a dual
eceptor antagonist, bosentan, throughout IH exposure.
ethods
ee the Online Appendix for an expanded Methods section.
xperimental Groups
ine-week-old male SHR and Wistar Kyoto rats (WKY)
ere exposed to IH 8 h per day for 14 consecutive days.
ontrol rats were exposed to normoxic cycles (N) only.
osentan-treated animals were fed bosentan-admixed chow
100 mg/kg/day) throughout the period of exposure.
unctional Studies
ystolic arterial blood pressure was measured by plethys-
ography throughout IH or N exposure and mean arterial
lood pressure (MABP) by arterial catheterization at day
5. Vascular and myocardial responses to intracoronary
T-1 and infarct size (after a 30-min global ischemia and a
20-min reperfusion sequence) were assessed in Langendorff-
erfused hearts at day 15.
mmunohistochemistry and Immunoblotting
mmunofluorescence staining with fluorescence microscopy
as performed on cryosections carefully matched for posi-
ion within the heart. Heart protein extracts were subjected
o Western blot analysis with the same antibodies used for
mmunostaining.
nzyme-Linked Immunoadsorbent Assays
yocardial ET-1 and big ET-1 levels as well as myocardial
IF-1 activation were quantified using enzyme-linked
mmunoadsorbent assays.
hromatin Immunoprecipitation Assay
yocardial chromatin immunoprecipitation was performed
s previously described (30), using an anti–HIF-1 anti-
ody and polymerase chain reaction (PCR) amplification of
he ET-1 gene promoter.
tatistical Analysis
xperimental data are presented as mean  standard error
f the mean. Levels of myocardial HIF-1 activation in SHR
ats exposed to N or IH were compared using a t test. All
ther data were analyzed using 2-way analysis of variance
ANOVA) (repeated measures ANOVA in the case of
ystolic arterial blood pressure) with Bonferroni post-hoc
omparisons. A value of p  0.05 was considered statisti-
ally significant.
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ffect of Genetic Susceptibility to Hypertension on the
esponse to IH
ardiovascular response. The effects of chronic IH on
ystemic blood pressure and myocardial susceptibility to
schemia were more pronounced in SHR. Thus, chronic IH
nhanced hypertension development in SHR, in particular
uring the second week of exposure ( systolic arterial blood
ressure: 28 11 mm Hg and 64 8 mm Hg at days 8 and
5 compared with 19  8 mm Hg and 33  7 mm Hg,
espectively, in N rats, p  0.001) while it did not
ignificantly affect blood pressure in WKY (: 16  9 mm
g at day 15) (Fig. 1A). This was confirmed by catheter
ecording at day 15 showing a significant effect of IH on
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Figure 1 Blood Pressure Response to Chronic IH or N
(A) Systolic arterial blood pressure measured by tail-cuff plethysmography
at days 1, 8, and 15. *p  0.001 versus day 1 (Bonferroni, 3 compari-
sons); **p  0.001 versus days 1 and 8 (Bonferroni, 3 comparisons);
‡p  0.001 versus Wistar Kyoto rats (WKY) (Bonferroni, 6 comparisons).
(B) Mean arterial blood pressure measured by carotid catheterization at day
15. †p  0.001 versus normoxia (N) rats; ‡p  0.01 versus WKY. Values are
mean  standard error of the mean (spontaneous hypertensive rats [SHR]:
n  27 to 29/group; WKY: n  15 to 16/group). IH  intermittent hypoxia.ABP in SHR (175  3 mm Hg vs. 147  4 mm Hg inrats, p  0.001) but not in WKY (Fig. 1B). Although
nfarct size values of WKY submitted to chronic IH tended
o be higher, a significant increase in infarct size was seen
nly in SHR (35  4% in IH vs. 21  3% in N rats, p 
.01) (Fig. 2).
IF-1 and ET system activation. CORONARY AND MYO-
ARDIAL RESPONSE TO ET-1. SHR exposed to IH exhibited a
reater increase in coronary perfusion pressure in response
o intracoronary ET-1 compared with SHR exposed to N or
o WKY (: 115  7 mm Hg vs. 81  7 mm Hg , 78 
mm Hg, and 77  7 mm Hg, respectively, in response to
.106 mol/l, p  0.01) (Fig. 3A). This was accompanied
y a significant increase in left ventricular end-diastolic
ressure (: 51  7 mm Hg vs. 2  8 mm Hg, 3  7 mm
g, and 4  8 mm Hg, respectively, in response to 3.106
ol/l, p  0.01) (Fig. 3B) and a significant decrease in left
entricular developed pressure (: 85  20 mm Hg vs.20
12 mm Hg, 24  10 mm Hg, and 8  10 mm Hg,
espectively, in response to 3.106 mol/l, p  0.01) (Fig. 3C).
YOCARDIAL AND CORONARY ET-A AND ET-B RECEPTOR EX-
RESSION. Myocardial expression of both ET-A and ET-B
eceptors was higher in SHR than in WKY. Moreover,
hronic IH induced an up-regulation in myocardial ET-A
n SHR only. ET-B receptor expression was not affected by
H (Fig. 4A). In accordance, immunofluorescent staining
howed a higher density of ET-1 receptors in coronary
rteries of SHR as well as an up-regulation of ET-A
eceptors with chronic IH in SHR only (Fig. 4B).
YOCARDIAL BIG-ET-1 AND ET-1 CONCENTRATIONS. Myocardial
ig ET-1 (13.4  4.0 pg/g compared with 3.6  0.8 pg/g
n N rats, p  0.01) and ET-1 (85.0  3.5 pg/g vs. 69.3 
.6 pg/g in N rats, p  0.01) levels were significantly
ncreased after exposure to chronic IH in SHR but not in
KY (Fig. 5). Specific activation of the ET system in SHR
xposed to IH resulted in a higher content of big ET-1 after
N IH N IH
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Figure 2 Infarct Size After Chronic IH or N
†p  0.01 versus N rats. Values are mean  standard
error of the mean (n  8 to 10/group). Abbreviations as in Figure 1.
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Endothelin in OSA-Related CVD April 14, 2009:1309–1730-min global ischemia in Langendorff-perfused hearts
increase of 597.2  192.0% compared with 119.2  37.5%
n WKY, p  0.01).
YOCARDIAL HIF-1 ACTIVATION AND TARGETING OF THE ET-1
ENE. In SHR, chronic exposure to IH induced a 1.6-fold
ncrease in activated myocardial HIF-1 (linked with
IF-1 to form HIF-1) in nuclear extracts (54.5  6.1
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Figure 3 Cardiac Effects of Intracoronary ET-1
Coronary perfusion pressure, left ventricular end-diastolic pressure, and left
ventricular developed pressure response to intracoronary bolus injections of
endothelin (ET)-1 (109 to 3.106 mol/l) in SHR and WKY submitted to chronic
IH or N. §p  0.01 versus the other groups (Bonferroni, 6 comparisons). Val-
ues are mean  standard error of the mean (n  7 to 8/group). Abbreviations
as in Figure 1.rbitrary units in IH vs. 35.2  3.7 arbitrary units in N rats, d 0.05) (Fig. 6A). In vivo chromatin immunoprecipita-
ion assay on myocardial extracts from SHR enabled us to
ross-link and immunoprecipitate myocardial HIF-1
ound to its target genes. Figures 6B and 6C show PCR
mplification of the hypoxia response element (HRE) site
roximal to the promoter of the myocardial ET-1 gene. The
ncrease in the PCR signal of the immunoprecipitated
raction from the IH group provided evidence that HIF-1
argeting of the myocardial ET-1 gene is induced by chronic
H in SHR. Lack of amplification in mock conditions
onfirmed the specificity of the immunoprecipitation tech-
ique. PCR signals from deoxyribonucleic acid fragments
efore immunoprecipitation (input) show that the immu-
oprecipitation results are not due to differences in sample
eoxyribonucleic acid content.
ffects of Bosentan Treatment
n SHR, oral bosentan administration throughout exposure
o N or IH completely prevented the IH-induced enhance-
ent of hypertension and increase in infarct size (24  3%
nd 25  2% in N and IH bosentan-treated rats, respec-
ively). Bosentan treatment did not, however, affect the
evelopment of genetically related hypertension (Fig. 7). In
KY, administration of bosentan was without effect (data
ot shown).
iscussion
SA is associated with cardiovascular diseases such as
ypertension, ischemic heart disease, and stroke and with
ncreased plasma ET levels. In this study, we found that
xposure of SHR to chronic IH in a manner similar to that
een in OSA patients resulted in enhanced hypertension
evelopment, increase in infarct size, and activation of the
T system and that bosentan treatment during IH exposure
ompletely prevented the deleterious cardiovascular alter-
tions. In addition, we established a critical role for HIF-1
n the up-regulation of the ET-1 gene in response to
hronic IH.
We have previously demonstrated that chronic IH en-
ances myocardial susceptibility to infarction in the rat (16).
his was also recently reported in mice and was shown to be
elated to increased oxidative stress (17). As for the hyper-
ensive effects of chronic IH, we were unable to observe a
ignificant increase in MABP after 35 days of exposure (16).
his is in accordance with some studies (31,32) but in
ontrast with others showing a moderate but statistically
ignificant increase in MABP in the rat (13,19,33). Overall,
he resulting effect of IH on blood pressure is thought to be
ritically dependent on the duration and severity of the IH
xposure. The results of the present study show that the
ardiovascular consequences of IH may also be determined
y pre-existing constitutional traits. Indeed, SHR were
ore susceptible to chronic IH, and this was evidenced by
ignificant increases in MABP and in infarct size after 14
ays of exposure that were not seen in WKY.
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April 14, 2009:1309–17 Endothelin in OSA-Related CVDWe propose that this increased susceptibility is due to a
nique hypoxia-dependent activation of the ET system in
HR, since such activation was not seen in WKY and since
osentan treatment completely prevented the deleterious
ardiovascular effects. In contrast to other animal models of
ypertension, hypertension development in SHR is not
elated to the ET system. Thus, SHR do not normally
xhibit enhanced ET-1 expression in blood vessels (34), and
hronic treatment with ET antagonists does not lower
lood pressure in SHR (29,35). Actually, our observation
hat bosentan treatment prevented the IH-induced but not
he genetically related increase in blood pressure is in
ccordance with these studies.
Nevertheless, SHR displayed an activation of the ET
ystem in response to chronic IH while WKY did not.
he basis for this paradoxical effect may lie in the results
f our chromatin immunoprecipitation assay analyzing
he interaction between HIF-1 and the myocardial
T-1 gene HRE. Hypoxia has been shown to induce ET
ranscription in several cell types including cardiomyo-
ytes (36) and endothelial cells (37). The HRE of the
uman and rat ET-1 promoter have been characterized
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Figure 4 Myocardial and Coronary ET-A and ET-B Receptor Exp
(A) Western-blot analysis of myocardial extracts from SHR and WKY submitted to
values. †p  0.05 versus N rats; ‡p  0.001 versus WKY. Values are mean  st
from SHR (S) and WKY (W). Red  receptors; blue  nuclei; 4 left panels  endo
ET-B receptors. Magnification: 600. ET-AR  ET-A receptors; ET-BR  ET-B recep38), and HIF-1 binding to the ET-1 gene after typoxia has been demonstrated in endothelial cells using
el shift assays (39). However, our study is the first to
rovide in vivo evidence of this interaction and, notably,
o report targeting of the cardiac ET-1 promoter by
IF-1 in SHR after chronic IH.
Activation of HIF-1 in response to chronic IH has been
emonstrated in vitro (40). In vivo, increases in tissue
IF-1 protein content have been reported (41,42), and
ata from mice with heterozygous HIF-1 deficiency have
rovided indirect evidence that HIF-1 is involved in chronic
H (43). In the current study, we have measured nuclear
IF-1 activity and have shown that it was significantly
ncreased in myocardial extracts from SHR submitted to
H, thus providing the first demonstration that HIF-1 is
ctivated in vivo in response to chronic IH.
While HIF-1 stabilization in sustained hypoxic condi-
ions is related to inhibition of prolyl hydroxylase activity,
here is increasing evidence that production of oxygen-
erived radicals, in particular superoxide anions, during IH
lays a major role in HIF-1 up-regulation (43,44), and a
allmark of hypertension development in SHR is increased
xidative stress (28,45). Thus, increased superoxide produc-
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Endothelin in OSA-Related CVD April 14, 2009:1309–17romoting HIF-1 activity and its subsequent targeting of
he ET-1 gene. In support for this hypothesis, Troncoso
rindeiro et al. (19) have shown that nicotinamide adenine
inucleotide phosphate oxidase activity and superoxide pro-
uction were elevated after IH exposure and that increases
n ET-1 synthesis and blood pressure could be prevented by
he superoxide dismutase mimetic tempol. In addition to
IF-1, other transcription factors known to modulate
T-1 gene expression, such as nuclear factor kappa B and
ctivator protein-1 (20), are activated by exposure to IH
46) and could also have played a role in the up-regulation
bserved in this study.
Our observation that HIF-1 targeting of the ET-1 gene
s responsible for the deleterious effects of chronic IH is
mportant since HIF-1 activation is known to be cardiopro-
ective (47). Indeed, we have shown that HIF-1 targeting of
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Figure 5 Myocardial Big ET-1 and ET-1 Levels
SHR and WKY submitted to chronic IH or N. †p  0.01 versus N rats. Values
are mean  standard error of the mean (n  7 to 8/group). ET  endothelin;
other abbreviations as in Figure 1.he inducible nitric oxide synthase gene results in cardio-N IH
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Figure 6 Myocardial HIF-1 Activation and
Targeting of the ET-1 Gene in SHR
(A) Myocardial hypoxia inducible factor (HIF)-1 activity in nuclear extracts from
SHR after 14 days of chronic IH or N. †p  0.05 versus N rats. Values are
mean  standard error of the mean (n  8/group). In vivo chromatin immuno-
precipitation of myocardial HIF-1 linked to the big endothelin-1 (ET-1) hypoxia
response element (HRE) (B) was performed in SHR after chronic IH or N.
(C) Polymerase chain reaction amplification of samples after immunoprecipita-
tion without (Mock) and with (IP) anti–HIF-1 antibody and of fragmented deoxyri-
bonucleic acid (DNA) before IP (Input). (D) Histogram representing polymerase
chain reaction performed on serial input dilutions confirming that amplification
is proportional to DNA quantity. OD  optic density; other abbreviations as in
Figure 1.
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April 14, 2009:1309–17 Endothelin in OSA-Related CVDrotection after acute exposure to IH (30). In accordance,
ice exposed to IH present a similar time course in
yocardial susceptibility to ischemia (17). It thus appears
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Figure 7 Effects of Bosentan Treatment
Effects of oral administration of bosentan (100 mg/kg/day) during chronic IH
or N in SHR. Systolic arterial blood pressure (A) was recorded at days 1, 8,
and 15. Mean arterial blood pressure (B) and infarct size (C) were assessed
at day 15. *p  0.05 versus day 1 (Bonferroni, 3 comparisons); **p  0.001
versus days 1 and 8 (Bonferroni, 3 comparisons); †p  0.001 versus N rats;
#p 0.05 versus untreated IH rats. Values are mean  standard error of the
mean (treated groups: n  7 to 8/group). Abbreviations as in Figure 1.hat with prolonged exposure, the beneficial effects are fiver-ridden, and this could be due to the repeated activation
f the ET-1 gene along with the enhanced expression of
T-1 receptors.
Indeed, SHR had, overall, a higher expression level of
oth ET-1 receptor subtypes in the myocardium com-
ared with WKY, a feature also observed in the kidney
48). However, in response to IH, SHR, but not WKY,
nderwent up-regulation of myocardial and, in particular,
f coronary ET-A receptors while ET-B receptors re-
ained unaffected. Similar results have been obtained by
llahdadi et al. (26), which have shown up-regulation of
T-A receptor in mesenteric arteries and more recently
n lung, renal medulla, and coronary arteries (49) after
hronic IH while ET-B receptor expression remained
nchanged. Overexpression of pulmonary ET, ET-A,
nd in some studies ET-B receptors is also seen in
esponse to chronic sustained hypoxia and is thought to
articipate in the development of pulmonary hyperten-
ion (50). Chronic hypoxia also increases the expression
f ET-1 and ET-A receptors in glomus cells of the
arotid body leading to increased hypoxic sensitivity (51).
hus, hypoxia appears to be a powerful stimulus for
T-1 receptor expression sufficient to overcome homol-
gous down-regulation. Interestingly, a recent study has
emonstrated the presence of several HRE in the human
T-B receptor promoter and has shown that HIF-1 can
p-regulate ET-B receptors (52). Whether the same
pplies to ET-A receptors remains to be demonstrated.
lso, organ culture studies have shown that protein
inase C and mitogen-activated protein kinase signaling
athways are involved in ET receptor up-regulation in
oronary arteries (53). This could provide the basis for
he ET receptor up-regulation induced by chronic IH in
HR since among the agents known to activate these
athways are reactive oxygen species and ET-1 itself
54,55).
Coronary ET-A up-regulation in SHR resulted in pro-
ounced vasoconstriction and myocardial dysfunction in
esponse to intracoronary ET-1. In view of the well-known
etrimental effects of ET-1 on the ischemic myocardium
56), this, along with the increased activation of the ET
ystem, which persisted in the ischemic myocardium, could
xplain the enhanced susceptibility to infarction induced by
hronic IH. The dramatic reduction in infarct size brought
bout by bosentan treatment is in agreement with this
ypothesis.
Although this is the first report of enhanced ET-1
asoconstriction in coronary arteries after chronic IH, in-
reased responses have been observed in other vascular
erritories (26,27). Thus, a generalized vascular hyper-
esponsiveness to ET-1 could account for the development
f hypertension, and this is supported by the preventive
ffects of ET-1 receptor blockade observed in various
tudies including the present one (18,49). A role for the ET
ystem in the IH-induced development of hypertension was
rst proposed by Kanagy et al. (18). In the current study,
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ion of the ET system by IH has far more widespread
onsequences resulting in hypertension development but
lso in aggravated infarction.
erspectives
ur findings in rats bring into light a potential treatment
trategy for the cardiovascular complications of OSA syn-
rome. Nocturnal application of CPAP is an effective and
afe treatment for sleep apnea. Although its regular use is
ssociated with a decrease in blood pressure and cardiovas-
ular risk (57), CPAP therapy is cumbersome and up to 30%
f OSA patients will discontinue their treatment over time
58). Alternative strategies could consist of targeting OSA
onsequences rather than eliminating apneas in noncompli-
nt patients. Given that some of the IH-induced cardiovas-
ular changes can be prevented by ET-1 blockade, the
ffects of ET-1 antagonist administration could be tested in
SA patients.
Another interesting clinical perspective brought about by
he present study is that, in OSA patients, susceptibility to
H and cardiovascular injury could be amplified by the
resence of comorbidities resulting in, among other things,
ncreased activation of HIF-1 and expression of deleterious
enes such as the ET-1 gene.
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APPENDIX
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tudy, please see the online version of this article.
